The European Union has approved a new oral pill form of Novo Nordisk’s weight-loss drug Wegovy, according to a Reuters report. This approval offers an alternative to the injectable version, potentially making treatment more accessible for people with obesity or overweight. The pill contains semaglutide, the same active ingredient as the injection.

Key takeaways

  • The EU approved an oral pill version of Wegovy (semaglutide) for weight management.
  • The pill provides an alternative to weekly injections, which some patients find inconvenient.
  • Approval was based on clinical trials that demonstrated efficacy and safety, as reported by Reuters.
  • Novo Nordisk aims to expand access to weight-loss treatments with this new formulation.

What is the Wegovy pill?

Wegovy is a brand name for semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes and later approved for chronic weight management. The injectable version has been widely used since its approval. The newly approved oral pill contains the same active ingredient but is taken by mouth, eliminating the need for injections. According to the Reuters report, the European Medicines Agency granted marketing authorization for the oral formulation, making it the first GLP-1 weight-loss pill available in the EU.

How does the pill compare to the injection?

The oral Wegovy pill offers a different route of administration compared to the once-weekly injection. Patients may prefer the convenience of a daily pill, especially those who are uncomfortable with needles or have difficulty storing injectable medications. However, the oral formulation may have different dosing requirements and absorption characteristics. The Reuters report noted that the approval was supported by clinical data showing that the pill led to significant weight loss compared to placebo, though specific numerical results were not detailed in the summary. It is important to note that both forms contain semaglutide and work by mimicking a hormone that regulates appetite and food intake.

What does this mean for patients?

For people in the European Union living with obesity or overweight, the oral Wegovy pill represents a new treatment option. It may improve adherence because some patients find daily pills easier to incorporate into their routine than weekly injections. The approval also signals a broader trend in obesity care toward more convenient drug delivery methods. According to the Reuters report, Novo Nordisk plans to make the pill available in EU markets soon, though pricing and insurance coverage details were not disclosed. Patients should consult their healthcare provider to determine if the oral formulation is appropriate for their individual health needs.

Clinical trial evidence

The EU approval was based on results from clinical trials that evaluated the safety and efficacy of oral semaglutide for weight management. While the Reuters summary did not provide specific trial data, it indicated that the studies met regulatory standards for approval. Previous research on oral semaglutide for diabetes has shown that it can lower blood sugar and promote weight loss. The oral formulation uses a special absorption enhancer to ensure the drug is effectively taken up by the body. As with any medication, side effects may include gastrointestinal issues such as nausea, vomiting, or diarrhea, which are common with GLP-1 drugs.

Frequently Asked Questions

Is the Wegovy pill as effective as the injection?

According to the Reuters report, clinical trials demonstrated that the oral pill led to significant weight loss. However, direct comparisons between the pill and the injection were not provided in the summary. In general, oral semaglutide has shown efficacy in lowering blood sugar and body weight in studies for diabetes, but the doses and absorption differ. Patients should discuss expected outcomes with their doctor.

Who can take the Wegovy pill?

The EU approval covers adults with obesity (body mass index of 30 or higher) or overweight (BMI of 27 or higher) who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. The pill is not intended for people with certain medical conditions, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. A healthcare provider can determine eligibility.

What are the common side effects of the Wegovy pill?

Based on known effects of semaglutide, common side effects of the oral pill may include nausea, vomiting, diarrhea, constipation, and abdominal pain. These gastrointestinal symptoms often decrease over time as the body adjusts. Serious side effects are rare but can include pancreatitis, gallbladder problems, and allergic reactions. Patients should report any persistent or severe symptoms to their doctor.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.